Replicor to Make Three Presentations at EASL 2016
Replicor Inc., a privately held biopharmaceutical company targeting a cure for chronic hepatitis B and D patients, today announced that it will present three abstracts at the EASL 2016 annual meeting to be held April 13-26, 2017 in Barcelona, Spain.
These presentations will disclose updated clinical, pre-clinical and mechanistic data on the activity of NAPs against chronic hepatitis B and hepatitis D infection:
- Updated clinical data from the ongoing REP 301 study assessing the safety and efficacy of REP 2139-Ca combined with pegylated interferon in patients with hepatitis B / hepatitis D co-infection (poster FRI-105).
- In vivo antiviral activity of REP 2139-Ca combined with tenofovir disoproxil fumarate and entecavir (poster THU-177).
- Immunostimulatory properties of REP 2139 and other NAP compounds (poster THU-204).
Replicor’s presentations will be available on the company’s website at the end of the conference at www.replicor.com/science/conference-presentations . For the 2016 EASL Meeting: http://ilc-congress.eu/ .
Replicor is a privately held biopharmaceutical company with the most advanced animal and human clinical data in the development of the cure for HBV and HDV. The company is dedicated to accelerating the development of an effective treatment for patients with HBV and HBV/HDV infection. For further information about Replicor please visit our website at www.replicor.com .
Makovsky for Replicor
Alexandra Peterson, 212-508-9709
Information om Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco
Følg pressemeddelelser fra Business Wire
Skriv dig op her og modtag pressemeddelelser på mail. Indtast din mail, klik på abonner og følg instruktionerne i den udsendte mail.
Flere pressemeddelelser fra Business Wire
DE-INCYTE21.10.2018 12:47 | pressemeddelelse
Incyte Announces Positive Interim Data from Phase 2 Trial of Pemigatinib, Its Selective FGFR Inhibitor, in Patients with Cholangiocarcinoma
SERVIER21.10.2018 11:12 | pressemeddelelse
Servier and Taiho Oncology Announce Phase III LONSURF® Study Has Met Primary and Secondary Endpoints Demonstrating Prolonged Overall Survival and Progression-Free Survival in Patients with Refractory Metastatic Gastric Cancer
IL-GILEAD-SCIENCES21.10.2018 00:32 | pressemeddelelse
Phase 3 Data on Filgotinib in Biologic-Experienced Rheumatoid Arthritis to Be Presented at 2018 ACR/ARHP Annual Meeting
CA-TRUE-RELIGION19.10.2018 19:39 | pressemeddelelse
Manchester United and True Religion Launch Denim Range
ARCH-INSURANCE19.10.2018 15:12 | pressemeddelelse
Arch Insurance Announces Strategic Leadership Changes
MA-TAKEDA-PHARMACEUTICAL19.10.2018 14:02 | pressemeddelelse
Takeda to Present Results from Phase 3 ALTA-1L Trial Highlighting Intracranial Efficacy of ALUNBRIG® (brigatinib) Versus Crizotinib in First-Line Advanced ALK+ Non-Small Cell Lung Cancer
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter, og finde vores kontaktoplysninger.Besøg vores nyhedsrum